Frey syndrome: treatment with type A botulinum toxin.

Department of Maxillofacial Surgery, University of Bonn, Bonn, Germany.
Cancer (Impact Factor: 4.89). 11/2000; 89(8):1659-63.
Source: PubMed


Frey syndrome was first described by Baillarger in 1853. Frey provided a detailed analysis and description as "auriculotemporal syndrome" in 1923. According to the literature, even the most recent therapeutic measures described for the treatment of patients with Frey syndrome have little chance of success and a high incidence of side effects. Thus, a type of treatment is desirable that can suppress the symptoms of Frey syndrome and can offer a good success rate, minimum invasiveness, and few side effects.
The experience of the authors and data from the literature confirmed the efficacy of type A botulinum toxin treatment for patients with Frey syndrome up to a maximum observation period of 3 years.
In the current study, seven patients with severe, symptomatic Frey syndrome after parotidectomy were treated successfully with type A botulinum toxin.
The method of local, intracutaneous treatment with type A botulinum toxin for patients with Frey syndrome is effective, virtually side-effect free, and minimally invasive.

Download full-text


Available from: Stefaan Berge, Jun 29, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To the Editor.— In the May 10, 1985, issue of JAMA, a question regarding management of Frey's syndrome was posed.1 Additional means for treatment of the symptomatic patient include topical scopolamine cream (0.1%), commercial antiperspirants, and tympanic neurectomy.2 Antiperspirants are of only occasional value, and scopolamine cream usually affords but temporary relief because the sweat glands become refractory. Tympanic neurectomy is indicated when the gustatory sweating is severe enough to embarrass the patient.
    JAMA The Journal of the American Medical Association 12/1985; 254(24):3421-3421. DOI:10.1001/jama.1985.03360240032009 · 35.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to evaluate the effects of sternocleidomastoid (SCM) muscle flap on preventing Frey’s syndrome by using, Galvanic skin responses (GSR). Fourty-three patients who underwent superficial parotidectomy were randomly divided into two groups and their GSR were recorded. SCM muscle flap was applied over the surgical area only in one group. Six months after the surgery, GSRs were remeasured. In addition, the patients completed a questionnaire regarding their complaints about clinical Frey’s syndrome. Four patients had symptoms of clinical Frey’s syndrome. Postoperative GSR measurements revealed no significant difference between two sides in flap group (p = 0.426) but higher in without flap group (p = 0.003). The patients with clinical Frey syndrome had significantly higher GSR values than the remaining patients. The SCM muscle flap was an effective method in preventing Frey’s syndrome. Moreover, GSR test was highly sensitive and specific for diagnosis.
    Indian Journal of Otolaryngology and Head & Neck Surgery 01/2014; 66(S1). DOI:10.1007/s12070-012-0492-y · 0.05 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In der vorliegenden Arbeit wurden die Daten von 250 Patienten, die zwischen 1993 und 2004 an der Glandula parotidea operiert worden waren, retrospektiv ausgewertet. Der Nachbeobachtungszeitraum musste mindestens 6 Monate betragen. Bei 146 Patienten wurde im Anschluss an eine Parotidektomie frei transplantiertes, abdominelles Fettgewebe in den Operationssitus eingebracht. Bei weiteren 104 Patienten wurde auf eine solche Augmentation verzichtet. Das Ziel war es, herausfinden, ob eine Bauchfettaugmentation nach Parotidektomie das kosmetische Ergebnis positiv beeinflusst, in wie weit das Auftreten eines Frey-Syndroms verhindert wird und ob eine Augmentation Auswirkungen auf die Wundheilung hat. Vereinzelt konnten sehr gute kosmetische Ergebnisse erzielt werden. Insgesamt zeigte sich jedoch kein signifikanter Unterschied in der kosmetischen Zufriedenheit zwischen den beiden Gruppen. Ein Frey-Syndrom trat mit 23% in der Gruppe der augmentierten Patienten signifikant seltener auf als in der nicht-augmentierten Gruppe (31%). Demgegenüber hatten die Patienten der augmentierten Gruppe signifikant häufiger eine Wundheilungsstörung (39%) als jene Patienten, bei welchen auf eine Augmentation verzichtet worden war (18%). Die Wundheilung wird somit durch Einbringen von Fettgewebe verzögert. Parotidectomy has aesthetic and functional sequelae, including Freys Syndrome and soft tissue depression of the auricular region. The purpose of this study was to evaluate the impact of using free subumbilical harvested fatty tissue. Between July 1993 and March 2004 a group of 250 patients undergoing parotidectomy met the study criteria having responded to the questionnaire and were included in this study. The minimum follow-up period was 6 months. Immediate augmentation was performed with a free subumbilical fatty graft in 146 cases. The results were compared with the outcomes of 104 patients who had been treated without reconstruction of the parotid bed. In selected cases, aesthetic results were very satisfactory, but no significant improvement was observed with using augmentation with fatty tissue. The majority of both groups were satisfied with the cosmetic outcomes. Frey Syndrome could be reduced significantly by placing a fatty graft into the defect. Patients who underwent conventional parotidectomy (without augmentation) showed increased gustatory sweating (23% to 31%). However, free fatty reconstruction following parotidectomy is associated with increased wound healing, 39% with fatty augmentation, whereas 18% of the control group developed wound healing disorder.
Show more